Objective: To study EPM2B gene mutations and genotype-phenotype correlations in patients with Lafora disease. Methods: The authors performed a clinical and mutational analysis of 25 patients, from 23 families, diagnosed with Lafora disease who had not shown mutations in the EPM2A gene. Results: The authors identified 18 mutations in EPM2B, including 12 novel mutations: 4 nonsense mutations (R265X, C26X, W219X, and E67X), a 6-base pair (bp) microdeletion resulting in a two amino acid deletion (V294_K295del), a 4-bp insertion resulting in a frameshift mutation (S339fs12), and 6 missense mutations (D308A, I198N, C68Y, E67Q, P264H, and D233A). In our data set of 77 families with Lafora disease, 54 (70.1%) tested probands have mutations in EPM2A, 21 (27.3%) in EPM2B, and 2 (2.6%) have no mutations in either gene. The course of the disease was longer in patients with EPM2B mutations vs patients with EPM2A mutations. Conclusions: Genetic allelic heterogeneity is present in Lafora disease associated with mutations in EPM2B. Patients with mutations in EPM2A and EPM2B express similar clinical manifestation, although patients with EPM2B-associated Lafora disease seem to have a slightly milder clinical course. The lack of mutations in EPM2A and EPM2B in two families could be because of the presence of mutations in noncoding, nontested regions or the existence of an additional gene associated with Lafora disease.
Lafora disease is characterized by epilepsy; fragmentary, segmental, and massive myoclonus; and rapid progressive mental deterioration. 1 EEG shows discharges of fast spike-wave and polyspike-wave complexes, photosensitivity, deterioration of background activity, and the appearance of multifocal abnormalities. Lafora disease is characterized by the presence of typical periodic acid-Schiff-positive (PAS) intracellular inclusion bodies (Lafora bodies) 2,3 composed of an abnormal glucose polymer that accumulate in the central and peripheral nervous system, among other tissues. 4, 5 Mutations in the EPM2A and EPM2B genes have been associated with Lafora disease. EPM2A, the major gene for Lafora disease, encodes a dual phosphatase known as laforin. 6, 7 More recently, a second gene associated with Lafora disease, EPM2B (also called NHLRC1), was reported. 8 EPM2B codes for a putative E3 ubiquitin ligase, 8 known as malin. EPM2B is a single-exon gene spanning 1,188 base pair (bp) and codes for a 395 amino acid protein, containing a zinc finger of the Ring type and six NHL-repeat protein-protein interaction domains. The most common mutation, P69A, is located in the Ring finger domain.
Methods. Clinical study. We studied 25 patients, from 23 families, diagnosed with Lafora disease who had no mutations in the EPM2A gene. Patients originated from five Mediterranean countries (Spain, Turkey, Italy, Serbia-Montenegro, and France) and Ecuador. Diagnosis was based on the presence of epilepsy, myoclonus, rapidly progressive neurologic deterioration, and slow background with polyspike-wave complexes on EEG. 1, 9 A skin, muscle, or liver biopsy also was required to confirm the presence of PASpositive intracellular inclusions (Lafora bodies). 2, 3, 10 To compare patients with EPM2B mutations and patients with EPM2A mutations, we also studied 70 patients, belonging to 54 families, diagnosed with Lafora disease who had mutations in the EPM2A gene.
Molecular study. Blood samples were obtained after patients or their legal guardians signed an Ethics Committee-approved consent form. Genomic DNA was extracted from peripheral blood leukocytes using standard proceedings. 11 Linkage to the EPM2A gene locus (chromosome 6q24) was excluded by using microsatellite polymorphic markers D6S1703, D6S1649, and D6S1049 (data not shown).
Using four appropriate primer pairs, 8 the coding exon of EPM2B was amplified by PCR using 40 ng of genomic DNA. The corresponding PCR products were purified using the Montage PCR Centrifugal Filter Device Kit (Millipore, Billerica, MA) and directly sequenced with an ABI PRISM 3700 genetic analyzer (Applied Biosystems, Foster City, CA). Analysis was performed using the ABI Analysis software (version 3.1).
Mutations found by sequence analysis were tested by singlestrand conformation analysis 12 in 100 control chromosomes using four additional pairs of primers (5'-ACCTCATAGAGCT-CCTGGG-3', 5'-GGGCTCAGCGCTTCGCC-3', 5'-TTAGCTCAAGT-ATGCAGCTTG-3', and 5'-GTCGGCCAAGTGGATACCT-3') for PCR amplification (GenePhor DNA Electrophoresis System, Amersham Pharmacia Biotech, Uppsala, Sweden). Samples were re-solved on 12.5% nondenaturing polyacrylamide gels using the GeneGel Exel 12.5/24 kit (Amersham Pharmacia Biotech) and silver stained using the PlusOne DNA Silver Staining Kit (Amersham Pharmacia Biotech).
To associate haplotypes with mutations and to analyze the possibility of a founder effect or recurrent mutations, polymorphic markers spanning the EPM2B gene region were typed (D6S1721, D6S1653, D6S1605, D6S1567, D6S1688, D6S285, D6S507, and D6S1691).
Statistical analysis. SPSS software (Chicago, IL) for Windows (Microsoft, Redmond, WA) version 10.0 was used for statistical analysis. We used 2 analysis-of-contingency tables (with Bonferroni corrections when appropriate) to compare data from patients with EPM2A and EPM2B mutations. Patients were classified in four groups according to years of progression of the disease (from first symptoms to death): 1) Ͻ5 years; 2) 5 to 10 years; 3) 10 to 15 years; and 4) Ͼ15 years of progression. We also classified patients according to the age at which patients died in three groups: 1) age 10 to 19 years; 2) 20 to 29 years; and 3) Ͼ30 years. A patient who is still alive at age 37 years was included in the third group. Significance was assumed if p Ͻ 0.05.
The Ethics Committee of the Fundación Jimenez Díaz Hospital approved this study.
Results. Molecular study. Of 25 patients (23 families) with biopsy-confirmed Lafora disease and no mutations in EPM2A, mutations in EPM2B were found in 23. In two patients, no mutations were identified. Consanguinity was not present in the families of these two patients, and linkage analysis could not exclude linkage to the known loci because of their small size and poor informative characteristics. However, in one of these families, the proband and her 26-year-old unaffected sister had different haplotypes at the EPM2A and EPM2B loci.
We identified 12 novel mutations: 4 nonsense mutations (R265X, C26X, W219X, and E67X), a 6-bp microdeletion resulting in a two amino acid deletion (V294_K295del), a 4-bp insertion resulting in a frameshift mutation (S339fs12), and 6 missense mutations (D308A, I198N, C68Y, E67Q, P264H, and D233A). We also found six previously reported mutations. 8 We also characterized the EPM2B haplotypes associated with each EPM2B mutation (table 1) . P69A is the predominant mutation and was present in 14 chromosomes from nine individuals belonging to nine families. Comparison of haplotypes in patients with the P69A mutation showed that only Families 86 and 103 shared a common haplotype.
Clinical study. The clinical and neurophysiologic features of 17 affected individuals with mutations in EPM2B belonging to 15 families are summarized in table 2. No clinical or neurophysiologic information could be obtained from six patients. Consanguinity was present in five families (21.7%). Age at onset ranged from 12 to 15 years in all patients, excluding affected individuals from Families 127 (22 years) and 143 (7 years). Six different initial symptoms were identified: 1) a generalized tonic-clonic seizure was the most common initial manifestation and was the first manifestation of the disease in 50% of the patients; 2) simple partial occipital seizures (18.7%); 3) partial seizures with secondary generalization (12.4%); 4) absences (6.3%); 5) myoclonic seizures (6.3%); and 6) hepatic disease (6.3%).
For individuals with mutations in EPM2A, we identified seven different initial symptoms: 1) generalized tonicclonic seizures (35.7%); 2) simple partial occipital seizures (17.8%); 3) partial seizures with secondary generalization (14.3%); 4) absences (14.3%); 5) myoclonic seizures (14.3%); 6) complex partial seizures (1.8%); and 7) hepatic disease (1.8%). Age at onset ranged from 8 to 17 years in all patients, excluding one affected individual with onset at 4 years. Age at which patients died ranged from 10 to 29 years, but most patients died between 19 and 29 years. In 65% of affected individuals, years of progression ranged from 5 to 10 years; in 25%, from 10 to 15 years; and in 10%, from 1 to 5 years.
Two illustrative cases of affected individuals with mutations in EPM2B are described below.
Patient 123-3. This patient had simple partial occipital seizures by age 12. The first myoclonic seizures occurred at age 13 to 14 years and were accompanied by generalized tonic-clonic seizures and absences. Photosensitivity was present. Inability to walk without assistance appeared at age 20 years. The patient died at age 35 years (years of progression, 23).
Patient 127-3. This patient had two isolated generalized tonic-clonic seizures at ages 5 and 6 years. The patient was in good health until age 22 years, when he had generalized tonic-clonic seizures. Since then, the neurologic picture has progressed slowly, with generalized tonic-clonic seizures, myoclonic seizures (onset, age 23 years), and cognitive decline (onset, age 28 years). At present, the patient shows resting and action myoclonus, mental deterioration, and cerebellar signs. Gait disturbance appeared at age 30 years. The EEG and skin biopsy were consistent with the diagnosis of Lafora disease. The patient is now age 37 years.
When we compared years of progression in patients with EPM2A and EPM2B mutations, we found that the course of the disease was longer in patients with mutations in EPM2B (p ϭ 0.011 and 0.033 using Bonferroni correction). We also found that the age at which patients died was higher in patients with EPM2B mutations than in patients with EPM2A mutations. For patients with EPM2A mutations, the mean age at which patients died was 20.85 years, and for patients with EPM2B mutations, the mean age of death was 25.67 years. The difference was significant (p ϭ 0.014 and 0.042 using Bonferroni correction). Two patients with mutations in EPM2B reached the fourth decade of life. No significant clinical differences were observed between patients with EPM2A and EPM2B mutations for other variables studied (age at onset, initial symptom, and photosensitivity).
Discussion.
In this report, we describe a systematic mutational analysis of the EPM2B gene in 46 chromosomes from 23 patients with Lafora disease (21 unrelated). We have identified 18 EPM2B mutations, 12 of them novel. In our series of 95 patients, 70 (73.7%) patients with Lafora disease had mutations in EPM2A and 23 (24.2%) in EPM2B, and in 2 patients (2.1%), no mutations were found in either gene. With respect to families, 54 (70.1%) families had mutations in EPM2A, and 21 (27.3%) had mutations in EPM2B; in 2 (2.6%) families, no mutations were found in either gene. Our data suggest that EPM2A and EPM2B are the major genes for Lafora disease, representing Ͼ95% of the patients.
We have also characterized the EPM2B haplotypes associated with each EPM2B mutation. P69A is the predominant mutation and was found in 14 chromosomes. We compared P69A mutation haplo-type constructions. Families 86 (France) and 103 (Spain) shared a common haplotype between D6S1653 and D6S285, suggesting a founder effect. The P69A mutation in the other families may have different phylogenetic origins, implying recurrence of the mutation. All other mutations were found only in one or two chromosomes. Failure to detect the second EPM2B mutation in one family (142) does not exclude the presence of a second mutation because we did not test noncoding regions, such as the promoter region. Lafora disease initially manifests during adolescence, the most common age at onset being between 10 and 17 years. 1 Patients die within less than a decade of first symptoms. Here we report 12 patients with EPM2B mutations with homogeneous clinical presentations and 5 additional patients with an atypical presentation (probands from Families 123, 127, 143, 146, and 176). The affected individual from Family 127 had a late onset (22 years) and is still alive at age 37 years. The affected patient from Family 123 had a long progression and died at age 35 years. It appears that in Lafora disease progression is longer if EPM2B is mutated. Statistical analysis confirmed this hypothesis.
An early-onset subphenotype consisting of cognitive deficit has been reported to be associated with mutations in the first exon of EPM2A. 13, 14 Here we report a patient (proband from Family 176) with learning disorder, followed by epilepsy and neurologic deterioration and a homozygous mutation in EPM2B. The mutation in Family 176 is located in an NHL protein-protein interaction domain. 15 It may be that additional factors besides the mutated exon or gene are involved in early-onset cognitive deficit. Interacting properties of laforin 16, 17 and malin may play an important role in this subphenotype.
Other families with atypical phenotypes are Families 143 and 146. The affected patient from Family 143 had an early age at onset (7 years) and has a long progression of 16 years (the patient is still alive). Both mutations of this patient are located in the Zn 2ϩ Ring finger domain, 18 as in Family 123, but no clinical similarities were found between affected of both families. In Family 146, the initial symptom was hepatic failure, and to date no neurologic manifestations have appeared. The mutation in this patient is also located in the Zn 2ϩ Ring finger domain.
The observed differences in the phenotypic expression between patients with EPM2A and EPM2B mutations could be because of the role of malin. Malin is a putative E3 ubiquitin ligase 8 involved in proteolysis cascades. 19, 20 It may be that other E3 ubiquitin Tonic ligases may reduce the effect of EPM2B mutations, increasing the years of progression and delaying the age at which patients die compared with those with EPM2A mutations.
